Hostname: page-component-6587cd75c8-9kljr Total loading time: 0 Render date: 2025-04-24T01:44:11.611Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-acting injectable antipsychotics: shall the last be first?

Published online by Cambridge University Press:  11 February 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Abstract

ISSUE:A paradigm shift is afoot in which the “last shall be first,” namely, use of long-acting injectable (LAI) antipsychotics, rather than being reserved for use only at the last stages of schizophrenia, may be shifting to first-line treatment of early episodes of this illness.

Type
Brainstorms
Information
CNS Spectrums , Volume 19 , Issue 1 , February 2014 , pp. 3 - 5
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Stahl, SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide, 5th ed. Cambridge, UK: Cambridge University Press; 2014.Google Scholar
2. Citrome, L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013; 13(7): 767–783.Google Scholar
3. Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63(10): 892–909.Google Scholar
4. Shi, L, Ascher-Svanum, H, Zhu, B, etal. Characteristics and use patterns of patients taking first generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv. 2007; 58(4): 482–488.Google Scholar
5. Munk-Jorgensen, P, Nielsen, J, Nielsen, RE, Stahl, SM. Last episode psychosis. Acta Psychiatr Scand. 2009; 119(6): 417–418.CrossRefGoogle ScholarPubMed
6. Morrisette, DA, Stahl, SM. Optimizing outcomes in schizophrenia: long acting depots and long term treatment. CNS Spectr. 2012; 17(Suppl 1): 10–21.Google Scholar
7. Morrissette, DA, Stahl, SM. Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? In: Ritsner MS, ed. Polypharmacy in Psychiatric Practice. Dordrecht, NL: Springer. Vol. I; 2012: 107–125.Google Scholar
8. van Haren, NE, Hulshoff Pol, HE, Schnack, HG, etal. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007; 32(10): 2057–2066.Google Scholar
9. Stahl, SM. Stahl;s Essential Psychopharmacology, 4th ed. Cambridge, UK: Cambridge University Press; 2013.Google Scholar
10. Agid, O, Arenovich, T, Sajeev, G, etal. An algorithm-based approach to first episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011; 72(11): 1439–1444.CrossRefGoogle ScholarPubMed
11. Kishimoto, T, Nitta, M, Borenstein, M, Kane, JM, Correll, CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013; 74(10): 957–965.Google Scholar
12. Tiihonen, J, Haukka, J, Taylor, M, etal. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011; 168(6): 603–609.Google Scholar
13. Rosenheck, RA, Krystal, JH, Lew, R, etal. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. New Engl J Med. 2011; 364(9): 842–851.Google Scholar
14. Subotnik, KL, Nuechterlein, KH, Ventura, J, etal. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011; 168(3): 286–292.Google Scholar